New treatment options for psoriasis based on new findings in the pathogenesis of psoriasis - risankizumab
2020
Abstract
Recently, new advances in our understanding of plaque psoriasis pathogenesis have clarified the key role of interleukin 23. The selective targeting of its p19 subunit is an attractive therapeutic option for a whole new category of biologic agents.
In this article, we describe the most recent efficacy and safety data regarding risankizumab, humanized IgG1 monoclonal antibody. Results of the recent studies offer evidence, that risankizumab provides the lonf-term high response rate (complete or almost complete skin clearance) without no additional safety concerns and with a lower overall drug exposure due to less frequent administration.